Articles by Yu-Tzu Chang in JoVE
Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms Bo-Jeng Wang*1, Pei-Yi Wu*1, Yun-Wen Chen*1, Yu-Tzu Chang1, Noopur Bhore1, Po-Fan Wu1, Yung-Feng Liao1 1Laboratory of Molecular Neurobiology, Institute of Cellular and Organismic Biology, Academia Sinica We have successfully generated two substrate-specific γ-secretase assays. Both cell-based assays presented here are designed to quantify γ-secretase enzymatic activities via the output of firefly luciferase reporters.
Other articles by Yu-Tzu Chang on PubMed
Estimation of Physical Functional Disabilities and Long-term Care Needs for Patients Under Maintenance Hemodialysis Medical Care. | Pubmed ID: 24300025 Physical functional disabilities in hemodialysis (HD) patients may increase their mortality and long-term care needs. The aim of this study was to estimate the changes of proportion for different physical functional disabilities along time after beginning HD and the lifelong care needs.
Cost-effectiveness of Hemodialysis and Peritoneal Dialysis: A National Cohort Study with 14 Years Follow-up and Matched for Comorbidities and Propensity Score Scientific Reports. | Pubmed ID: 27461186 Although treatment for the dialysis population is resource intensive, a cost-effectiveness analysis comparing hemodialysis (HD) and peritoneal dialysis (PD) by matched pairs is still lacking. After matching for clinical characteristics and propensity scores, we identified 4,285 pairs of incident HD and PD patients from a Taiwanese national cohort during 1998-2010. Survival and healthcare expenditure were calculated by data of 14-year follow-up and subsequently extrapolated to lifetime estimates under the assumption of constant excess hazard. We performed a cross-sectional EQ-5D survey on 179 matched pairs of prevalent HD and PD patients of varying dialysis vintages from 12 dialysis units. The product of survival probability and the mean utility value at each time point (dialysis vintage) were summed up throughout lifetime to obtain the quality-adjusted life expectancy (QALE). The results revealed the estimated life expectancy between HD and PD were nearly equal (19.11 versus 19.08 years). The QALE's were also similar, whereas average lifetime healthcare costs were higher in HD than PD (237,795 versus 204,442 USD) and the cost-effectiveness ratios for PD and HD were 13,681 and 16,643 USD per quality-adjusted life year, respectively. In conclusion, PD is more cost-effective than HD, of which the major determinants were the costs for the dialysis modality and its associated complications.